MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Cerrado

3.69 -0.54

Resumen

Variación precio

24h

Actual

Mínimo

3.66

Máximo

3.7199999999999998

Métricas clave

By Trading Economics

Ingresos

44M

-26M

Ventas

-5.8M

42M

Margen de beneficio

-61.388

Empleados

550

EBITDA

44M

-22M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+14.56% upside

Dividendos

By Dow Jones

Próximas Ganancias

17 mar 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

360M

1.4B

Apertura anterior

4.23

Cierre anterior

3.69

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

26 ene 2026, 23:49 UTC

Acciones populares

Stocks to Watch: Agilysys, Nucor, Humana, UnitedHealth

26 ene 2026, 23:09 UTC

Principales Movimientos del Mercado

Health Insurers' Shares Fall After Government Proposes Flat Medicare Advantage Rate

26 ene 2026, 23:52 UTC

Charlas de Mercado

Gold's Path of Least Resistance Still Looks Higher, Technical Analysis Shows -- Market Talk

26 ene 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Decline as Yen's Rebound Raises Caution Over Earnings -- Market Talk

26 ene 2026, 23:37 UTC

Charlas de Mercado

Gold Rises Amid Concerns Over Tariffs -- Market Talk

26 ene 2026, 22:41 UTC

Charlas de Mercado

Australian 4Q CPI To Provide Smoking Gun For Hike -- Market Talk

26 ene 2026, 22:26 UTC

Ganancias

Karoon Expects Capex of US$110 Million-US$135 Million in 2026

26 ene 2026, 22:26 UTC

Ganancias

Karoon Expects Operating Costs to Fall Once Transition of Bauna FPSO Operatorship Completes

26 ene 2026, 22:25 UTC

Ganancias

Karoon Energy Expects Unit Production Cost of US$12-US$15/BOE in 2026

26 ene 2026, 22:25 UTC

Ganancias

Karoon Energy Expects Output to Rise in 2H Following Bauna Investment Program

26 ene 2026, 22:25 UTC

Ganancias

Karoon Energy Expects Output of 8.1 Million-9.2 Million BOE in 2026

26 ene 2026, 22:24 UTC

Ganancias

Karoon Energy 4Q Sales Revenue US$156.1 Million

26 ene 2026, 22:23 UTC

Ganancias

Karoon Energy 4Q Sales Volumes 2.65 Million BOE, Up 5% on Quarter

26 ene 2026, 22:23 UTC

Ganancias

Karoon Energy: Bauna FPSO Efficiency Increased to 98.8%

26 ene 2026, 22:23 UTC

Ganancias

Karoon Energy FY Oil, Natural Gas Production 10.3 Million BOE

26 ene 2026, 22:22 UTC

Ganancias

Karoon Energy 4Q Oil, Natural Gas Production 2.37 Million BOE

26 ene 2026, 22:05 UTC

Adquisiciones, fusiones, absorciones

Fortescue: Alta Copper Shareholders Approve Takeover

26 ene 2026, 22:02 UTC

Adquisiciones, fusiones, absorciones

Senate Antitrust Panel Chair Raises Concerns Over Netflix-Warner Deal -- WSJ

26 ene 2026, 21:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

26 ene 2026, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

26 ene 2026, 21:34 UTC

Ganancias

Nucor: Steel Products Segment Expected Improved Earnings in 1Q Due to Increased Volumes on Stable Pricing >NUE

26 ene 2026, 21:34 UTC

Ganancias

Nucor: Steel Mills Segment Expected Increase Is Due to Higher Volumes and Higher Realized Prices Across All Major Pdt Categories >NUE

26 ene 2026, 21:34 UTC

Ganancias

Nucor: Raw Materials Segment Is Expected to Have Increased Earnings in 1Q >NUE

26 ene 2026, 21:34 UTC

Ganancias

Nucor: 1Q Earnings Expected to Increase Across All Three Operating Segments, With the Largest Increase in Steel Mills Segment >NUE

26 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Eaton Stock Rises on Spin-Off Plan. Why It's Going All-In on Planes and AI Data Centers. -- Barrons.com

26 ene 2026, 21:30 UTC

Ganancias

Nucor 4Q Sales $7.69B >NUE

26 ene 2026, 21:30 UTC

Ganancias

Nucor 4Q Net $378M >NUE

26 ene 2026, 21:30 UTC

Ganancias

Nucor 4Q Steel Mills Total Shipments 5.91M Tons >NUE

26 ene 2026, 21:30 UTC

Ganancias

Nucor 4Q Total Tons Shipped to Outside Customers Down 9% >NUE

26 ene 2026, 21:30 UTC

Ganancias

Nucor 4Q EPS $1.64 >NUE

Comparación entre iguales

Cambio de precio

Maravai LifeSciences Holdings Inc (Class A) Esperado

Precio Objetivo

By TipRanks

14.56% repunte

Estimación a 12 meses

Media 4.25 USD  14.56%

Máximo 4.5 USD

Mínimo 4 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Maravai LifeSciences Holdings Inc (Class A) Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

3

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.02 / 2.115Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat